Hospira irinotecan hydrochloride trihydrate IV Infusion 100 mg

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

irinotecan hydrochloride trihydrate, Quantity: 20 mg/mL

Disponible depuis:

Hospira Australia Pty Ltd

DCI (Dénomination commune internationale):

irinotecan hydrochloride trihydrate

forme pharmaceutique:

Injection, intravenous infusion

Composition:

Excipient Ingredients: lactic acid; sorbitol; water for injections

Mode d'administration:

Intravenous Infusion

Unités en paquet:

1 x 5 mL vial

classe:

Medicine Listed (Export Only)

Type d'ordonnance:

(S1) This Schedule is intentionally blank

indications thérapeutiques:

Small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, ovarian cancer, stomach cancer (inoperable or recurrent), colorectal cancer (inoperable or recurrent), breast cancer (inoperable or recurrent), squamous cell carcinoma, malignant lymphoma (non Hodgkin's disease).

Descriptif du produit:

Visual Identification: A clear, colourless to pale yellow solution; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 36 Months; Container Temperature: Room temperature; Container Closure: Neither child resistant closure nor restricted flow insert

Statut de autorisation:

Licence status A

Date de l'autorisation:

2013-01-31